Intellia Therapeutics (NTLA) News Today $13.12 -1.01 (-7.15%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Intellia Therapeutics (NASDAQ:NTLA) Given New $91.00 Price Target at Chardan CapitalNovember 21 at 5:41 AM | americanbankingnews.comWells Fargo & Company Cuts Intellia Therapeutics (NASDAQ:NTLA) Price Target to $70.00November 21 at 5:41 AM | americanbankingnews.comIntellia Therapeutics Announces Promising CRISPR Therapy ResultsNovember 20 at 3:27 AM | finance.yahoo.comCathie Wood’s ARK Investment buys 223.5K shares of Intellia Therapeutics todayNovember 20 at 3:27 AM | markets.businessinsider.comIntellia Therapeutics' (NTLA) Neutral Rating Reiterated at William BlairNovember 20 at 2:51 AM | americanbankingnews.comIntellia’s gene editing therapy shows early potential in rare heart conditionNovember 19 at 6:33 AM | msn.comIntellia Therapeutics price target lowered to $70 from $80 at Wells FargoNovember 19 at 6:33 AM | markets.businessinsider.comIntellia Therapeutics’ NTLA-2001 Shows Promising Potential with Positive Phase 1 Data and Accelerated Phase 3 EnrollmentNovember 19 at 6:33 AM | markets.businessinsider.comIntellia Therapeutics' Gene Therapies Fall Short Of Breakthroughs (Rating Downgrade)November 19 at 12:05 AM | seekingalpha.comWells Fargo & Company Issues Pessimistic Forecast for Intellia Therapeutics (NASDAQ:NTLA) Stock PriceWells Fargo & Company reduced their target price on shares of Intellia Therapeutics from $80.00 to $70.00 and set an "overweight" rating for the company in a research note on Monday.November 18 at 1:41 PM | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Sees Unusually-High Trading Volume Following Analyst UpgradeIntellia Therapeutics (NASDAQ:NTLA) Sees Strong Trading Volume After Analyst UpgradeNovember 18 at 1:17 PM | marketbeat.comIntellia Therapeutics' (NTLA) Neutral Rating Reaffirmed at WedbushWedbush reissued a "neutral" rating and issued a $14.00 target price on shares of Intellia Therapeutics in a research report on Monday.November 18 at 11:40 AM | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Given Neutral Rating at William BlairWilliam Blair restated a "neutral" rating and issued a $14.00 price target on shares of Intellia Therapeutics in a research note on Monday.November 18 at 11:40 AM | marketbeat.comChardan Capital Boosts Intellia Therapeutics (NASDAQ:NTLA) Price Target to $91.00Chardan Capital upped their target price on Intellia Therapeutics from $88.00 to $91.00 and gave the stock a "buy" rating in a report on Monday.November 18 at 10:40 AM | marketbeat.comIntellia Therapeutics: Buy Rating Driven by Promising Efficacy and Safety of Nex-Z TreatmentNovember 17, 2024 | markets.businessinsider.comIntellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) AmyloidosisNovember 16, 2024 | globenewswire.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Average Recommendation of "Moderate Buy" from AnalystsNovember 16, 2024 | americanbankingnews.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Average Rating of "Moderate Buy" from BrokeragesShares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the sixteen brokerages that are covering the company, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a hold rating, ten have issuNovember 16, 2024 | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Reaches New 1-Year Low - Here's WhyIntellia Therapeutics (NASDAQ:NTLA) Reaches New 1-Year Low - What's Next?November 15, 2024 | marketbeat.comSumitomo Mitsui Trust Group Inc. Sells 108,290 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)Sumitomo Mitsui Trust Group Inc. cut its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 3.3% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 3,149,399 shares of the company's stock afNovember 15, 2024 | marketbeat.comIntellia Therapeutics: Buy Rating Affirmed on Promising NTLA-2001 Data and Upcoming CatalystsNovember 14, 2024 | markets.businessinsider.comIntellia Therapeutics (NTLA) Gets a Buy from Truist FinancialNovember 12, 2024 | markets.businessinsider.comIntellia Therapeutics price target lowered to $60 from $70 at OppenheimerNovember 11, 2024 | markets.businessinsider.comOppenheimer Lowers Intellia Therapeutics (NASDAQ:NTLA) Price Target to $60.00Oppenheimer cut their price objective on Intellia Therapeutics from $70.00 to $60.00 and set an "outperform" rating for the company in a report on Monday.November 11, 2024 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA), Veeva Systems (VEEV) and Neuren Pharmaceuticals Limited (OtherNURPF)November 11, 2024 | markets.businessinsider.comIntellia Therapeutics: Q3 Earnings Report Puts Phase II Results In FocusNovember 11, 2024 | seekingalpha.com3 Fast-Growing Stocks Analysts See Doubling in PriceClinical-stage biotech firms often have massive upside potential, but much of that possible success hinges on successful trials and product launches.November 11, 2024 | marketbeat.comBrookline Capital Management Estimates NTLA FY2027 EarningsIntellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) - Investment analysts at Brookline Capital Management lowered their FY2027 EPS estimates for Intellia Therapeutics in a research note issued on Thursday, November 7th. Brookline Capital Management analyst L. Cann now forecasts that the compaNovember 11, 2024 | marketbeat.comEvercore ISI Keeps Their Buy Rating on Intellia Therapeutics (NTLA)November 9, 2024 | markets.businessinsider.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Just Reported Third-Quarter Earnings And Analysts Are Lifting Their EstimatesNovember 9, 2024 | finance.yahoo.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Q3 2024 Earnings Call TranscriptNovember 9, 2024 | msn.comIntellia Therapeutics (NASDAQ:NTLA) Upgraded at StockNews.comStockNews.com upgraded shares of Intellia Therapeutics to a "sell" rating in a research report on Friday.November 8, 2024 | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Releases Earnings Results, Beats Expectations By $0.03 EPSIntellia Therapeutics (NASDAQ:NTLA - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($1.34) earnings per share for the quarter, beating the consensus estimate of ($1.37) by $0.03. The company had revenue of $9.10 million during the quarter, compared to the consensus estimate of $8.28 million. During the same period in the prior year, the company earned ($1.38) earnings per share. The firm's revenue was down 24.1% compared to the same quarter last year.November 8, 2024 | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Price Target Cut to $55.00 by Analysts at BarclaysBarclays decreased their price objective on Intellia Therapeutics from $76.00 to $55.00 and set an "overweight" rating for the company in a report on Friday.November 8, 2024 | marketbeat.comCautious Optimism: Intellia Therapeutics Hold Rating Amidst Promising Trial Developments and Financial StabilityNovember 8, 2024 | markets.businessinsider.comWells Fargo Sticks to Their Buy Rating for Intellia Therapeutics (NTLA)November 8, 2024 | markets.businessinsider.comIntellia Therapeutics price target lowered to $55 from $76 at BarclaysNovember 8, 2024 | msn.comARK Investment Management LLC Acquires 659,651 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)ARK Investment Management LLC boosted its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 5.7% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 12,255,440 shares of the company's stock after acquiring aNovember 8, 2024 | marketbeat.comIntellia Tops Revenue EstimatesNovember 8, 2024 | fool.comIntellia Therapeutics: Promising Gene-Editing Advancements and Strong Financial Position Support Buy RatingNovember 8, 2024 | markets.businessinsider.comIntellia Therapeutics’ Strategic Advancements and Promising NTLA-2001 Progress Boost Buy RatingNovember 8, 2024 | markets.businessinsider.comIntellia Therapeutics, Inc. (NTLA) Q3 2024 Earnings Call TranscriptNovember 7, 2024 | seekingalpha.comIntellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company ProgressNovember 7, 2024 | globenewswire.comIntellia Therapeutics Just Notched Another Win. So Why Did Its Stock Fall 18% in 1 Day?November 6, 2024 | fool.comHarbor Capital Advisors Inc. Has $1.63 Million Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)Harbor Capital Advisors Inc. increased its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 71.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 79,205 shares of the company's stock afterNovember 6, 2024 | marketbeat.comIntellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)November 5, 2024 | globenewswire.comIntellia Therapeutics (NTLA) Set to Announce Quarterly Earnings on ThursdayIntellia Therapeutics (NASDAQ:NTLA) will be releasing earnings before the market opens on Thursday, November 7, Zacks reports.November 5, 2024 | marketbeat.comIntellia Therapeutics: Positive Outlook and Buy Rating Amid Promising Data for ATTR-CM TreatmentNovember 4, 2024 | markets.businessinsider.comThis Beaten-Down Stock Could Soar by 354%, According to Wall StreetNovember 4, 2024 | fool.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Sold by Capital Advisors Inc. OKCapital Advisors Inc. OK trimmed its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 34.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 203,775 shares of the company's stock after selling 107,November 2, 2024 | marketbeat.com Get Intellia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter. Email Address Financial Prophecy (Ad)The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier. Including the name of the #1 company to buy. NTLA Media Mentions By Week NTLA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NTLA News Sentiment▼0.510.45▲Average Medical News Sentiment NTLA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NTLA Articles This Week▼247▲NTLA Articles Average Week Get Intellia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Celldex Therapeutics News Sangamo Therapeutics News Editas Medicine News Cellectis News CRISPR Therapeutics News Viking Therapeutics News Lantheus News Crinetics Pharmaceuticals News Avidity Biosciences News Krystal Biotech News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NTLA) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intellia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intellia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
